Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals. • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2012IS041 Principal Investigator Bachanova, Veronika
Phase Phase III
Age Group Adult Scope National
Secondary Protocol No. C25003
Title HM2012-21: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Objective This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL).
Treatment Experimental: A+AVD consists of brentuximab vedotin (ADCETRIS) 1.2 mg/kg plus doxorubicin 25 mg/m2, vinblastine 6 mg/m2, and dacarbazine (DTIC) 375 mg/m2. Active Comparator: ABVD consists of doxorubicin 25 mg/m2, bleomycin 10 units/m2, vinblastine 6 mg/m2, and dacarbazine (DTIC) 375 mg/m2.
Description This open-label, randomized, 2-arm, multicenter, phase 3 study will enroll patients into 1 of 2 treatment arms. A+AVD and ABVD will be administered intravenously on Days 1 and 15 of each 28-day cycle. Patients may receive up to 6 cycles of planned study therapy.
Key Eligibility Patient must have histologically confirmed classical Hodgkin Lymphoma (HL) .
Applicable Disease Sites Hodgkin's Lymphoma
Brentuximab vendotin (ADCETRIS)
Status Open
Participating Institutions Masonic Cancer Center
Detailed Eligibility Must be at least 18 years of age, be treatment-naive and have bidimensional measurable disease. Anyone with nodular lymphocyte predominant Hodgkin lymphoma, cerebral/meningeal disease, sensory or peripheral neuropathy or known HIV positive is not eligible. A signed informed consent and HIPAA authorization are required.
Treatment Type Treatment
Contact Veronika Bachanova Phone:612-625-5469
  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on